Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
Offers oral solid dosage development linking formulation, process development, and risk assessment with the QTPP, for clinical and commercial supply.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| RNA / LNP service capabilities | Project-dependent / not verified · Project-dependent / not verified | Services / platform | This record does not establish human validation of the entire platform |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Recipharm has added a sterile cream and ointment line at its Odivelas site in Portugal. The line accommodates aluminum and polyfoil tubes from 3.5 to 30 grams, with annual output of 8 million to 15 million units depending on fill volume and batch size. It complements existing multidose ophthalmic manufacturing and is ready for new customer projects.
Recipharm has extended high-potency oral solid dose manufacturing at Leganés, Spain, to GMP pilot scale. A contained suite combines dry granulation, tableting, and coating for compounds up to OEB 5. The same pilot equipment can support clinical and small commercial batches, with larger programs transferring to commercial lines at the same site rather than another facility.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
